DA
CRVS icon

DCF Advisers’s Corvus Pharmaceuticals CRVS Stock Holding History

DCF Advisers’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,500
Closed -$10K – 102
2025
Q2 		$10K Sell
2,500
-2,500
-50% -$9.1K ﹤0.01% 84
2025
Q1 		$15.9K Buy
+5,000
New +$23.6K 0.01% 85

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DCF Advisers's CRVS Position: Q1 2026 in Review

DCF Advisers reduced its Corvus Pharmaceuticals (CRVS) stake by 13% in Q1 2026, selling an estimated $1.46M and leaving 637,500 shares worth $9.33M. The position accounts for 2.49% of the portfolio, ranked #7.

DCF Advisers first reported a position in CRVS in Q1 2025 and has held it in 4 quarters since. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

  • DCF Advisers held 637,500 shares of Corvus Pharmaceuticals worth $9.33M as of Q1 2026.
  • DCF Advisers sold 91,500 Corvus Pharmaceuticals shares in Q1 2026, an estimated $1.46M.
  • Corvus Pharmaceuticals made up 2.49% of DCF Advisers's portfolio in Q1 2026, its #7 holding.
  • DCF Advisers first reported a position in Corvus Pharmaceuticals in Q1 2025 and has held it in 4 quarters since.
  • 164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on DCF Advisers's 13F filing for Q1 2026, filed 11 May 2026.